The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease

Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease

October 1, 2012 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BERLIN—Two studies presented here show promising new approaches in systemic sclerosis that could help with treatment and prediction of worsening symptoms.

You Might Also Like
  • Targeted Therapy for Scleroderma Fibrosis
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
  • New Osteoporosis Drugs Show Promise in Therapy Pipeline
Explore This Issue
October 2012
Also By This Author
  • Rheumatology Research Foundation Scholarships Help Students Attend ACR/ARHP Annual Meeting

Investigators out of the United Kingdom presented findings on a goat serum as a new treatment for established diffuse cutaneous systemic sclerosis (SSc) and a team from Belgium and Italy showed how a nailfold test might be helpful in predicting future organ involvement in several types of SSc. The work was presented in a session at the European League Against Rheumatism (EULAR) 2012 Annual European Congress of Rheumatology, held June 6–9.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Serum from Goats Could Combat SSc

Researchers from the University College London treated 20 subjects with diffuse cutaneous SSc—10 with goat serum and 10 with a placebo. Subjects must have had diffuse SSc for at least three years and no longer be on disease-modifying antirheumatic drugs, and they could not have had a previous lymphoma or any malignancy in the past five years. They also could not have active tuberculosis or hepatitis B or C, any opportunistic infections, or any progressive or active organ disease.

The hyperimmune caprine serum product, called Aimspro, is derived from serum obtained from a herd of specially vaccinated goats, certified as scrapie-free, in Tasmania. It has already been given Orphan Drug Approval for chronic inflammatory demyelinating polyradiculoneuropathy and motor neuron disease in Australia and for amyotrophic lateral sclerosis in the U.S.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The subcutaneous Aimspro injections were given twice weekly, the first d

Niamh Quillinan, MD, clinical research fellow at University College London, said the findings establish safety and feasibility, with a similar number of serious adverse events in both groups (six events in three patients in the placebo group and four in three patients in the goat serum group). Two subjects withdrew due to adverse events in each group.

Researchers found that the mean skin score fell by 1.4 in those on active treatment after 26 weeks but got worse in the patients on placebo, by an average of 2.1 points. The study wasn’t large enough for statistical significance on that point. However, analysis suggested a clinically meaningful improvement in half of the patients on active treatment, compared with one in the placebo group (p=.01).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

There are logistic challenges with the drug, since it has to be stored at -20 degrees Celsius (-4 degrees Fahrenheit).

“These data confirm the safety and tolerability of a novel biological agent in a complex multisystem autoimmune rheumatic disease,” Dr. Quillinan said. “Improvement in 50% of subjects receiving active medication versus 10% on placebo warrants further investigation.”

Test to Predict Organ Involvement in SSc

Researchers at Ghent University Hospital in Belgium and University Sapienza and the University of Genova in Italy are proposing that nailfold video capillaroscopy (NVC) might be able to predict severe clinical organ involvement in systemic sclerosis patients.

Pages: 1 2 | Single Page

Filed Under: Conditions, Meeting Reports, Research Reviews, Scleroderma Tagged With: drug, EULAR, International, labs, patient care, Research, Scleroderma, Systemic sclerosisIssue: October 2012

You Might Also Like:
  • Targeted Therapy for Scleroderma Fibrosis
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
  • New Osteoporosis Drugs Show Promise in Therapy Pipeline
  • EULAR 2012: Systemic Sclerosis That Doesn’t Fit the Mold

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)